Xeris Biopharma
Markets Recorlev, Gvoke and Keveyis while advancing formulation-based drug programs.
$8.48
After-hours close+0.00 (+0.06%)
At close$8.48(−1.45%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 64.29%111.00M sharesInsiders 5.28%9.12M sharesOther 30.43%52.53M shares
Shares outstanding 172.64M · Float 164.66M · 95.4% free float
Institutions13F, as of Jun 30, 2026
249 holders · 111.00M shares · 37 new positions · 147 increased · 62 reduced · 30 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 14.53M | 8.41% | +1.58M | Aug 7, 2026 |
| D. E. Shaw & Co., Inc. | 7.80M | 4.52% | +15.9K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 7.34M | 4.25% | +359.3K | Aug 13, 2026 |
| State Street Corp | 4.82M | 2.79% | +163.4K | Aug 7, 2026 |
| Geode Capital Management, LLC | 4.72M | 2.73% | +427.6K | Aug 12, 2026 |
| Nuveen, LLC | 4.39M | 2.54% | +1.47M | Aug 11, 2026 |
| Rosalind Advisors, Inc. | 2.91M | 1.68% | −322.7K | Aug 14, 2026 |
| Qube Research & Technologies Ltd | 2.89M | 1.68% | −1.22M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Vanguard Capital Management | 5.00% | 8.64M | 13G | Jul 31, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| John Patrick Jr Shannon | director, officer: See Remarks | 2.90M | 1.68% | Aug 21, 2026 |
| Kevin McCulloch | officer: See Remarks | 1.65M | 0.96% | Aug 21, 2026 |
| Steven Pieper | officer: See Remarks | 1.36M | 0.79% | Aug 12, 2026 |
| Beth Hecht | officer: See Remarks | 1.14M | 0.66% | Aug 4, 2026 |
| John Johnson | director | 683.1K | 0.40% | Jun 5, 2026 |
| Anh Tu Nguyen | officer: See Remarks | 398.7K | 0.23% | Feb 25, 2026 |
| Garheng Kong | director | 238.3K | 0.14% | Jun 5, 2026 |
| Jeffrey W. Sherman | director | 219.2K | 0.13% | Aug 29, 2025 |
| Marla Persky | director | 150.7K | 0.09% | Jun 5, 2026 |
| Barbara-Jean Anne Bormann-Kennedy | director | 126.5K | 0.07% | Jun 5, 2026 |
3 ten-percent owners hold 4.79M shares by Form 4, outside the officers-and-directors figure above · 6 people have not refiled in the last 18 months (5.20M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 12, 2026 | Steven Pieperofficer: See Remarks | Sale | 5,000 | $8.50 | 1,361,053 |
| Aug 3, 2026 | Beth Hechtofficer: See Remarks | Sale | 16,666 | $8.01 | 1,144,462 |
| Aug 3, 2026 | Kevin McCullochofficer: See Remarks | Sale | 15,000 | $8.02 | 1,676,126 |
| Jul 7, 2026 | Steven Pieperofficer: See Remarks | Sale | 27,600 | $8.52 | 1,366,053 |
| Jul 6, 2026 | Steven Pieperofficer: See Remarks | Sale | 17,400 | $8.50 | 1,393,653 |
| Jul 1, 2026 | Beth Hechtofficer: See Remarks | Sale | 16,666 | $8.03 | 1,161,128 |
| Jul 1, 2026 | Kevin McCullochofficer: See Remarks | Sale | 90,000 | $8.03 | 1,691,126 |
| Jun 4, 2026 | John Johnsondirector | Sale | 15,000 | $6.09 | 683,083 |
| Jun 4, 2026 | Barbara-Jean Anne Bormann-Kennedydirector | Sale | 16,000 | $6.09 | 126,500 |
| Jun 4, 2026 | Dawn Halkuffdirector | Sale | 20,000 | $6.09 | 95,000 |
CongressHouse and Senate disclosures
Not reported.